The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1424 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 August 2022 | Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended. |
| 20 July 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nintedanib for untreated malignant pleural mesothelioma. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 09 March 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of nintedanib for untreated malignant pleural mesothelioma. Following a recent update from the company, NICE has decided to suspend this appraisal on its work programme. As the appraisal has been referred, NICE will continue to monitor any developments and will provide a further update in due course. |
| 09 March 2020 | Suspended. Topic is suspended |
| 11 June 2018 - 09 July 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 24 April 2018 | In progress. DHSC Referral Received |
For further information on our processes and methods, please see our CHTE processes and methods manual